Sage Capital Stock vs Net Invested Capital Analysis
SAGE Stock | USD 5.54 0.19 3.32% |
Sage Therapeutic financial indicator trend analysis is much more than just breaking down Sage Therapeutic prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sage Therapeutic is a good investment. Please check the relationship between Sage Therapeutic Capital Stock and its Net Invested Capital accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.
Capital Stock vs Net Invested Capital
Capital Stock vs Net Invested Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sage Therapeutic Capital Stock account and Net Invested Capital. At this time, the significance of the direction appears to have strong relationship.
The correlation between Sage Therapeutic's Capital Stock and Net Invested Capital is 0.64. Overlapping area represents the amount of variation of Capital Stock that can explain the historical movement of Net Invested Capital in the same time period over historical financial statements of Sage Therapeutic, assuming nothing else is changed. The correlation between historical values of Sage Therapeutic's Capital Stock and Net Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Stock of Sage Therapeutic are associated (or correlated) with its Net Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Invested Capital has no effect on the direction of Capital Stock i.e., Sage Therapeutic's Capital Stock and Net Invested Capital go up and down completely randomly.
Correlation Coefficient | 0.64 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Capital Stock
The total amount of a company's capital funded by shareholders through the issue and subscription of shares.Net Invested Capital
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.Most indicators from Sage Therapeutic's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sage Therapeutic current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.The current year's Enterprise Value is expected to grow to about 1.8 B, whereas Selling General Administrative is forecasted to decline to about 144.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 2.9M | 14.2M | 36.1M | 37.9M | Net Interest Income | 2.9M | 14.2M | 36.1M | 37.9M |
Sage Therapeutic fundamental ratios Correlations
Click cells to compare fundamentals
Sage Therapeutic Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sage Therapeutic fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.1B | 2.2B | 1.8B | 1.4B | 882.3M | 873.1M | |
Other Current Liab | 86.6M | 46.2M | 59.8M | 65.0M | 62.1M | 41.5M | |
Total Current Liabilities | 112.1M | 67.2M | 85.2M | 99.3M | 82.7M | 59.3M | |
Total Stockholder Equity | 944.7M | 2.1B | 1.7B | 1.3B | 799.5M | 802.6M | |
Property Plant And Equipment Net | 42.9M | 31.8M | 19.1M | 13.4M | 6.4M | 11.8M | |
Net Debt | (89.6M) | (1.6B) | (275.8M) | (150.6M) | (65.8M) | (69.1M) | |
Retained Earnings | (1.6B) | (1.0B) | (1.5B) | (2.0B) | (2.6B) | (2.4B) | |
Accounts Payable | 15.3M | 3.7M | 10.5M | 19.0M | 10.3M | 11.5M | |
Cash | 126.7M | 1.7B | 294.2M | 162.7M | 71.0M | 67.4M | |
Non Current Assets Total | 49.1M | 36.9M | 24.6M | 84.0M | 12.9M | 20.5M | |
Non Currrent Assets Other | 3.8M | 3.3M | 4.3M | 69.3M | 6.5M | 8.4M | |
Other Assets | 6.2M | 5.1M | 5.5M | 6.0M | 6.9M | 7.3M | |
Cash And Short Term Investments | 1.0B | 2.1B | 1.7B | 1.3B | 753.2M | 829.1M | |
Common Stock Shares Outstanding | 50.8M | 53.0M | 58.7M | 59.3M | 59.8M | 45.7M | |
Liabilities And Stockholders Equity | 1.1B | 2.2B | 1.8B | 1.4B | 882.3M | 873.1M | |
Non Current Liabilities Total | 3.7M | 27.4M | 19.7M | 11.1M | 4.6M | 0.0 | |
Other Current Assets | 26.7M | 45.6M | 39.8M | 50.8M | 30.3M | 21.1M | |
Other Stockholder Equity | 2.6B | 3.1B | 3.2B | 3.3B | 3.4B | 1.8B | |
Total Liab | 139.5M | 86.9M | 96.3M | 103.9M | 82.7M | 70.5M | |
Property Plant And Equipment Gross | 42.9M | 31.8M | 24.1M | 19.5M | 13.9M | 13.2M | |
Total Current Assets | 1.0B | 2.1B | 1.8B | 1.3B | 869.4M | 852.6M | |
Accumulated Other Comprehensive Income | 1.3M | 415K | (2.7M) | (10.2M) | (814K) | (854.7K) | |
Property Plant Equipment | 9.1M | 6.8M | 19.1M | 2.9M | 3.3M | 5.0M | |
Other Liab | 3.7M | 519K | 270K | 100K | 115K | 109.3K | |
Net Tangible Assets | 944.7M | 2.1B | 1.7B | 1.3B | 1.4B | 977.9M | |
Retained Earnings Total Equity | (1.6B) | (1.0B) | (1.5B) | (2.0B) | (1.8B) | (1.7B) | |
Short Term Investments | 881.7M | 438.5M | 1.4B | 1.1B | 682.2M | 630.7M | |
Capital Surpluse | 2.6B | 3.1B | 3.2B | 3.3B | 3.8B | 2.0B | |
Non Current Liabilities Other | 27.4M | 19.7M | 11.1M | 4.6M | 5.3M | 8.5M | |
Net Invested Capital | 944.7M | 2.1B | 1.7B | 1.3B | 799.5M | 1.3B | |
Net Working Capital | 923.0M | 2.1B | 1.7B | 1.2B | 786.6M | 1.3B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sage Therapeutic is a strong investment it is important to analyze Sage Therapeutic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sage Therapeutic's future performance. For an informed investment choice regarding Sage Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.57) | Revenue Per Share 1.76 | Quarterly Revenue Growth 3.371 | Return On Assets (0.30) | Return On Equity (0.49) |
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.